4MLH
Human Glucokinase in Complex with a Novel Amino Thiazole Allosteric Activator
4MLH の概要
| エントリーDOI | 10.2210/pdb4mlh/pdb |
| 関連するPDBエントリー | 4MLE |
| 分子名称 | Glucokinase, alpha-D-glucopyranose, 3-(benzyloxy)-5-methyl-N-(4-methyl-1,3-thiazol-2-yl)pyridin-2-amine (3 entities in total) |
| 機能のキーワード | sugar kinase, allosteric activator, small molecule, transferase-transferase activator complex, transferase/transferase activator |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 51500.55 |
| 構造登録者 | |
| 主引用文献 | Hinklin, R.J.,Boyd, S.A.,Chicarelli, M.J.,Condroski, K.R.,Dewolf, W.E.,Lee, P.A.,Lee, W.,Singh, A.,Thomas, L.,Voegtli, W.C.,Williams, L.,Aicher, T.D. Identification of a New Class of Glucokinase Activators through Structure-Based Design. J.Med.Chem., 56:7669-7678, 2013 Cited by PubMed Abstract: Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high glucose concentrations. Glucose flux through GK also contributes to reducing hepatic glucose output. Because many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, compounds that can activate GK may serve as effective treatments for type 2 diabetes. Herein we report the identification and initial optimization of a novel series of allosteric glucokinase activators (GKAs). We discovered an initial thiazolylamino pyridine-based hit that was optimized using a structure-based design strategy and identified 26 as an early lead. Compound 26 demonstrated a good balance of in vitro potency and enzyme kinetic parameters and demonstrated blood glucose reductions in oral glucose tolerance tests in both C57BL/6J mice and high-fat fed Zucker diabetic fatty rats. PubMed: 24015910DOI: 10.1021/jm401116k 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.9 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






